Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fickert

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Journal of Hepatology|May 23, 2017
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitisPeter Fickert, Gideon M Hirschfield, Gerald Denk, et al.
Endoscopy|April 19, 2017
Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical GuidelineLars Aabakken, Tom H Karlsen, Jörg Albert, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|November 13, 2018
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survivalFlorian Kleinegger, Eva Hofer, Christina Wodlej, et al.
Journal of Lipid Research|March 22, 2019
Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humansGernot F Grabner, Nermeen Fawzy, Maria A Pribasnig, et al.
Science Translational Medicine|August 13, 2025
FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesityKatrin Panzitt, Emilian Jungwirth, Lena E Vosko, et al.
Journal of Hepatology|May 1, 2018
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasisMarion J Pollheimer, Silvia Racedo, Amanda Mikels-Vigdal, et al.
Wiener Klinische Wochenschrift|October 25, 2017
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)Thomas Reiberger, Andreas Püspök, Maria Schoder, et al.
Oncotarget|December 20, 2017
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, et al.
Oncotarget|February 6, 2023
Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Journal of Hepatology|May 23, 2017
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitisPeter Fickert, Gideon M Hirschfield, Gerald Denk, et al.
Endoscopy|April 19, 2017
Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical GuidelineLars Aabakken, Tom H Karlsen, Jörg Albert, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|November 13, 2018
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survivalFlorian Kleinegger, Eva Hofer, Christina Wodlej, et al.
Journal of Lipid Research|March 22, 2019
Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humansGernot F Grabner, Nermeen Fawzy, Maria A Pribasnig, et al.
Science Translational Medicine|August 13, 2025
FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesityKatrin Panzitt, Emilian Jungwirth, Lena E Vosko, et al.
Journal of Hepatology|May 1, 2018
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasisMarion J Pollheimer, Silvia Racedo, Amanda Mikels-Vigdal, et al.
Wiener Klinische Wochenschrift|October 25, 2017
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)Thomas Reiberger, Andreas Püspök, Maria Schoder, et al.
Oncotarget|December 20, 2017
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, et al.
Oncotarget|February 6, 2023
Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, et al.
Pageof 17